Biomarkers May Separately Predict New Preserved- and Low-LVEF HF Biomarkers May Separately Predict New Preserved- and Low-LVEF HF

Two types of heart failure, two ways to predict its onset: The different biomarker arrays for each HF type seem to reflect poorly understood differences in underlying causes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news

Related Links:

We present a case of a high-output lower extremity superficial femoral artery (SFA) -femoral vein (FV) arteriovenous fistula resulting in right heart failure and distal deep venous thrombosis managed with a covered arterial stent-graft.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: Abstracts Presented to the Southern California Vascular Surgery Society Source Type: research
We report the case of a 66-year old gentleman who was transferred to our facility with acute abdominal pain. A computed tomography (CT) scan was obtained after pre-medication because of contrast dye allergy. His past medical history included a cardiac transplant and congestive heart failure (ejection fraction 20%).
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: Abstracts Presented to the Southern California Vascular Surgery Society Source Type: research
Conclusions: Our study suggests that baseline galectin-3 is an independent predictor of LVRR. Low levels of galectin-3 may be regarded a useful biomarker of favorable ventricular remodeling in patients with RODCM. PMID: 30018673 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
In conclusion, LAZ3 protects against cardiac remodeling in DCM by decreasing miR-21, thus regulating PPARa/NRF2 signaling.
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
Publication date: Available online 19 July 2018Source: Microchemical JournalAuthor(s): Bahia Abbas Moussa, Hanaa M.A. Hashem, Marianne Alphonse Mahrouse, Sally Tarek MahmoudAbstractEntresto® tablets (sacubitril/valsartan combination) were recently approved by FDA to reduce the risk of cardiovascular death in patients with chronic heart failure. Entresto® is usually administered in conjunction with rosuvastatin. Sacubitril inhibits organic anion-transporting polypeptides (OATP) responsible for the uptake of rosuvastatin into human hepatocytes. The aim of this investigation was to evaluate OATP-mediated drug interact...
Source: Microchemical Journal - Category: Chemistry Source Type: research
Researchers in this study looked at how participating hospitals performed in Medicare’s Bundled Payments for Care Improvement initiative for five medical conditions (congestive heart failure, pneumonia, chronic obstructive pulmonary disease, sepsis, and acute myocardial infarction) and compared them with matched control hospitals. Hospitals in the initiative did not have lower costs or other better outcomes compared with those not participating. Bundling for medical conditions may require more time, new care strategies and partnerships, or additional incentives.        
Source: The Commonwealth Fund: Publications - Category: International Medicine & Public Health Source Type: research
THURSDAY, July 19, 2018 -- Several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure, are being recalled due to an impurity, N-nitrosodimethylamine, that has been found in the recalled...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Medtronic (NYSE:MDT) said today it launched a new clinical trial evaluating the use of its ECG belt research system as a diagnostic tool for improving cardiac resynchronization therapy for heart failure patients. The Fridley, Minn.-based company said it has enrolled the first patients in the trial at Des Moines, Iowa’s Mercy Medical Center – West Lakes by principal investigator Dr. Troy Hounshell. “The aim of this technology is to give physicians immediate feedback that may impact clinical decision making at the time of implant and also during follow-up visits. By pairing CRT with the ECG Belt, we ha...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news
Optimal site selection &image fusion guidance technology to facilitate cardiac resynchronisation therapy. Expert Rev Med Devices. 2018 Jul 18;: Authors: Sieniewicz BJ, Gould J, Porter B, Sidhu BS, Behar JM, Claridge S, Niederer S, Rinaldi CA Abstract INTRODUCTION: Cardiac resynchronisation therapy (CRT) has emerged as one of the few effective treatments for heart failure. However, up to 50% of patients derive no benefit. Suboptimal LV lead position is a potential cause of poor outcomes whilst targeted lead deployment has been associated with enhanced response rates. Image-fusion guidance systems re...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research
Conditions:   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV Intervention:   Drug: Loop Diuretics Sponsor:   University of Turin, Italy Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Health | Heart | Heart Failure